VistaGen Therapeutics

-$0.0148 (-1.63%) Today
-$0.0052 (-0.58%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTGN and other ETFs, options, and stocks.

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy.

CEO
Shawn K. Singh
Employees
36
Headquarters
South San Francisco, California
Founded
1998

VTGN Key Statistics

Market cap
184.99M
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.63M
High today
$0.9579
Low today
$0.876
Open price
$0.9001
Volume
1.82M
52 Week high
$3.55
52 Week low
$0.86

VTGN News

BenzingaJun 28

Looking Into VistaGen Therapeutics's Return On Capital Employed

Benzinga Pro data, VistaGen Therapeutics VTGN reported Q4 sales of $38.90 thousand. Earnings fell to a loss of $16.69 million, resulting in a 58.41% decrease fr

VTGN Earnings

-$0.30
-$0.21
-$0.11
-$0.02
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
-$0.06 per share
Actual
-$0.09 per share
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure